

cost per QALY for LET is under the implicit threshold of \$50,000 per QALY gained, and 96% and 81% chance of a similar result for ANA and EXE, respectively.

Conclusions: Treatment with aromatase inhibitors (LET, ANA and EXE) is cost-effective in postmenopausal women with early breast cancer compared to TAM. Despite the higher acquisition cost of LET, the mean cost-effectiveness of LET vs TAM is lower than the mean cost-effectiveness of ANA or EXE vs TAM.

2093 POSTER Detection of postoperative lymphoedema in patients with breast cancer

M. Halaska¹, P. Strnad¹, J. Chod¹, I. Mala², H. Stankusova³, P. Feldmar¹, L. Rob¹. ¹Charles University, Dept. of OB/GYN, Prague, Czech Republic; ²University of Economics, Dept. of Statistics, Prague, Czech Republic; ³Charles University, Dept. of Oncology and Radiotherapy, Prague, Czech Republic

Background: Lymphoedema is a severe postoperative complication after the treatment of many malignancies. It is represented by a pathological accumulation of extracellular water (ECW). Several diagnostic tools are available, but all of the currently used methods use a measurement of total limb volume to detect lymphoedema. Multifrequency bioimpedance analysis (MFBIA) is a promising method for early detection of changes in ECW.

Material and Methods: Between August 2004 and February 2007 a group of 74 patients undergoing breast cancer surgery was measured by MFBIA and circumference measurement one day before surgery and every 3 months for 18 months after the surgery. A control group of 72 healthy women was measured. MFBIA measurements in the control group were used to calculate standard deviation (S.D.). One-tailed interval confidence interval was used for the detection of lymphoedema. Characteristics of the patients and healthy women were recorded. The detection of lymphoedema was done using MFBIA, circumference measurement and upon the symptoms given by the patients.

Results: The average age in the control and tested group was 40.1 and 58.9 years. S.D. from the control group was 0.0827. The average size of the tumor, grade, and positivity of estrogen receptors was 15.1 mm, 2.04 and 43%. In 23 patients (21%) axillary lymph node dissection of level I and II was performed (ALND), in 51 patients (79%) a biopsy of sentinel lymph node (SLNB) without ALND was performed. Lymphoedema was detected in 8 women (11%). In these patients MFBIA detected lymphoedema 9 months earlier in total than other methods. Out of these 8 women 5 women (63%) underwent ALND, 3 women (37%) underwent SLNB only.

Conclusions: MFBIA is a low-cost and precise method for the detection of early stage postoperative lymphoedema. We recommend incorporating MFBIA into standard follow-up plan of every patient undergoing surgery of breast cancer combined with circumference measurement.

The work was supported by a Grant of Ministry of Health IGA MZ NR 9455-3.

2094 POSTER 5-year follow up of nipple areolar sparing mastectomy with immediate breast reconstruction for breast cancer

S.H. Kang, S.J. Lee, N.W. Baek, E.M. Kim. Yeungnam University Medical Center, General Surgery, Daegu, Korea

Backgrounds: Nipple-areolar preservation is a logical step in the ever more conservative management of breast cancer. Although there is substantial literature to support the oncologic safety of skin sparing mastectomy (SSM), few investigators have reported their long-term experience with procedures that spare the nipple areola complex (NAC). We report here the 5 year follow-up result of nipple-areola-skin sparing mastectomy (NASSM).

Materials and Methods: From 1990 to 2005, 176 patients underwent SSM (54 mastectomies) or NASSM (124 mastectomies), with 2 patients undergoing bilateral operation, yielding a total of 178 mastectomies. No patients received radiotherapy. During performing NASSM, frozen section analysis of the tissue beneath NAC was performed. After the procedure, all patients were followed-up for evidence of recurrence.

Results: The mean age of patients was 39.8 years (ranges, 20-59 years). NAC base was positive in 29.2% patients at definitive histology with false-negative results in 1.6% patients at intraoperative frozen section. Neoplastic NAC involvement was more common in tumor with invasive histology ($p=0.024$) and with extensive intraductal component ($p=0.025$). Other primary tumor characteristics, including multicentricity and location, were not predictive for neoplastic NAC invasion. During the mean follow-up of 61.2 months for NASSM patients and 43.6 months for SSM patients, 10 (8.1%) of 124 NASSM patients and 4 (7.4%) of 54 SSM patients developed local recurrences (LR) ($p>0.5$). Local recurrence free interval was not

different between the two groups (log rank test, $p>0.5$). All LRs were detected easily, by patient or routine follow-up check of 6-month interval, and manageable surgically. One patient in SSM group developed distant metastasis at 24 months after the treatment of LR.

Conclusions: Our results suggest that, using the frozen-section analysis of NAC during operation, nipple areola preservation can be a reasonable option for selected patients who want immediate breast reconstruction.

2095 POSTER A randomized, open-label CECOG phase II study of dose-dense FEC 75 vs FEC 90 as adjuvant therapy in early breast cancer patients

S. Kahan¹, S. Spanik², M. Wagnerova³, T. Skacel⁴, B. Planko⁵, E. Fitzthum⁶, E. Lindner⁶, V. Soldatenkova⁷, C.C. Zielinski⁸, T. Brodowicz⁸. ¹Onkoterápiás Klinika, Oncology, Szeged, Hungary; ²Onkol. Ustav Sv. Albety, Oncology, Bratislava, Slovak Republic; ³Oncology Institute, Department of Radiotherapy and Oncology, Kosice, Slovak Republic; ⁴Amgen(Europe) Hematooncology, Internal Medicine Charles University Prague, Prague, Czech Republic; ⁵CECOG, Projectmanagement, Vienna, Austria; ⁶CEMA, Pharmaceutical Monitoring Agency, Vienna, Austria; ⁷InnoPharm, Smolensk, Russian Federation; ⁸Division of Oncology, Department of Medicine 1 Med. University of Vienna, Vienna, Austria

Purpose: Anthracyclines are regarded as the standard of care of adjuvant chemotherapy in patients (pts) with early breast cancer. Recently, dose-dense regimens have attracted much attention in this setting by improving outcomes vs. conventional schedule regimens. This trial assessed the feasibility of delivering two dose-dense fluorouracil/epirubicin/cyclophosphamide (FEC) regimens, as well as evaluating their relative efficacy and safety.

Characteristics

		Arm A: FEC75 (n = 25) N (%)	Arm B: FEC90 (n = 26) N (%)
Strata			
Mean age, yrs (±SD)		51(10)	51(9)
		N (%)	N (%)
Axillary lymph nodes	Negative	6 (24)	5 (19)
	Positive	19 (76)	21 (81)
ER status:	Negative	15 (60)	11 (42)
	Positive	10 (40)	15 (58)
PR status:	Negative	13 (52)	14 (54)
	Positive	12 (48)	12 (46)
Menopausal status:	Pre	11 (44)	10 (39)
	Post	14 (56)	16 (61)
Stage:	I	2 (8)	3 (12)
	II	19 (76)	19 (73)
	III	4 (16)	4 (15)

Results

	Arm A: FEC75 N (%)	Arm B: FEC90 N (%)
Pts ≥85% RDI	24 (96)	23 (89)
Dose delays (out of 147/143 infusions in Arm A/B)	6 (4)	14 (10)
Dose reductions (out of 147/143 infusions in Arm A/B)	0	1 (1)
G3/4 Toxicities:		
Leukopenia	0	1 (4)
Neutropenia	0	1 (4)
Thrombocytopenia	0	0
Anemia	0	1 (4)
ANC <0.5 × 10 ⁹ /L for >5 days	0	0
ANC <0.1 × 10 ⁹ /L for >3 days	0	0
Febrile neutropenia	0	0

Patients and Methods: Patients with early breast cancer suitable for surgical resection at three centers in two countries were randomized, open-label to receive adjuvant FEC with epirubicin 75 mg/2 (FEC75; Arm A) or 90 mg/2 (FEC90; Arm B). Chemotherapy was given every 2 weeks for up to 6 cycles. Pegfilgrastim (6 mg sc) was administered in both arms on day 2 of each treatment cycle. The primary endpoint was the proportion of

patients with relative dose intensity (RDI) $\geq 85\%$, with secondary objectives of incidences of dose delays and dose reductions due to neutropenic events, toxicity and disease free survival.

Results: Between May 2005 and May 2006 51 pts were recruited (25 Arm A, 26 Arm B). Baseline demographics and disease characteristics are shown in the table, as is RDI and the incidence of hematological toxicities.

Conclusions: In this study, proportion of patients with RDI $\geq 85\%$ was 96% and 89% in pegfilgrastim augmented dose-dense FEC75 and FEC90 arms. No patient experienced febrile neutropenia and there were only single occurrences of grade 3–4 leukopenia and neutropenia. Thus, within the short time period assessed, these initial data suggest that both regimens are safe in the adjuvant treatment of early breast cancer.

Oral presentations (Tue, 25 Sep, 09.00–11.00)

Breast cancer – advanced disease

2096

ORAL

Lapatinib (L) plus Capecitabine (C) in HER2+ advanced breast cancer (ABC): report of updated efficacy and gene-array data

J. Crown¹, D. Cameron², A.M. Martin³, B. Newstat³, T. Pienkowski⁴, A. Jagiello-Gruszfeld⁵, B. Kaufman⁶, M.A. Casey³, S. Stein³, C. Geyer⁷.

¹St. Vincent's Hospital, Medical Oncology, Dublin, Ireland; ²University of Leeds, Oncology, Leeds, United Kingdom; ³GlaxoSmithKline, Oncology Medicine Development Center, Collegeville, USA; ⁴Centrum Onkologii Klinika Nowotworów Piersi i Chirurgii, Oncology, Warszawa, Poland; ⁵KliZOS MSWiA, Chemotherapy, Olsztyn, Poland; ⁶Chaim Sheba Medical Center, Oncology, Tel-Hashomer, Israel; ⁷Allegheny General Hospital, Oncology, Pittsburgh, USA

Background: EGF100151 demonstrated L+C improved TTP relative to C alone in women with HER2+, trastuzumab-exposed ABC [Geyer, NEJM 2006; 355(26)]. We report updated efficacy results and correlative studies to determine if differential gene expression levels are associated with clinical benefit of L+C.

Methods: Tumor blocks were available for 217/399 patients; sufficient mRNA was extracted from 103/217 patient tumor blocks for evaluation of gene expression by qRT-PCR and by Affymetrix HU133 plus 2.0 gene expression arrays. SpotFire™ DecisionTree analysis was performed on the qRT-PCR data to determine the genes significantly associated with RR; genes were further analyzed for association with TTP using Kaplan Meier survival analyses. Preliminary gene array data were analyzed, to date only in the combination arm, using a Wilcoxon's test (cut-off $p < 0.01$) to determine genes with significant differential expression between the responders and non-responders.

Results: Efficacy results as of April 3, 2006: TTP L+C 27 wk vs C 19 wk, HR 0.57 [0.43, 0.77], $p = 0.00013$; ORR L+C 24% vs C 14%, Odds Ratio 1.9 [1, 1.34], $p = 0.017$; OS L+C vs C HR 0.78 [0.55, 1.12], $p = 0.177$; progression in CNS L+C 2% vs C 11%, $p = 0.0445$. Amongst 103 patients with mRNA data, there were 19 responders (PR = 19), 26 non-responders (SD = 20, PD = 6) and NE = 10 in L+C; 5 responders (PR = 5), 22 non-responders (SD = 20, PD = 12) and NE = 8 in C. Preliminary analysis of gene array data show elevated baseline HER2 mRNA expression correlates with response to L+C ($p < 0.01$) in L+C. This finding was confirmed by qRT-PCR data where elevated baseline HER2 mRNA expression is associated with higher RR as well as longer TTP ($p < 0.0001$) with L+C. In addition, gene array data revealed that patients with elevated baseline FOX3A mRNA levels and reduced baseline BCL-2 mRNA responded to L+C in the combination arm alone; consistent with preclinical response data in breast cancer cell lines.

Conclusion: Updated efficacy results confirm the prior demonstrated benefit of L+C vs C and provide evidence for systemic anti-HER2 therapy effects on the development of CNS metastases. Preliminary data suggest a correlation between elevated HER2 mRNA levels and RR/TTP. In addition, preliminary gene array data suggest that patients whose tumours have increased regulation of HER signaling and induction of apoptotic pathways gain greater clinical benefit from treatment with L+C. Additional array analyses will be discussed from both treatment arms.

2097

ORAL

Biomarker analysis of lapatinib with paclitaxel versus paclitaxel as first-line treatment in 580 patients with metastatic breast cancer

R.S. Finn¹, M.F. Press², J. Dering¹, H. Gomez³, Z. Aziz⁴, M. Arbushtes⁵, M. Koehler⁵, C. Oliva⁵, L.S. Williams⁵, A. Di Leo⁶. ¹Geffen School of Medicine at UCLA, Los Angeles CA, USA; ²Keck School of Medicine of the University of Southern California, Los Angeles CA, USA; ³Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; ⁴Allama Iqbal Medical College, Lahore, Pakistan; ⁵GlaxoSmithKline, Clinical, Collegeville PA, USA; ⁶Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy

Background: Lapatinib is an oral tyrosine kinase inhibitor of EGFR/HER2 that was recently approved in US for use in combination with capecitabine for HER2-overexpressing (HER2+) advanced/metastatic breast cancer (BC) pretreated with taxanes, anthracyclines, and trastuzumab-based therapy. Paclitaxel has shown activity alone and in combination for HER2+ BC. We report here an analysis on HER2, ER, and PR for 580 patients (pts) with incurable Stage IIb/IIIc/IV BC at first diagnosis or relapse whose HER2 status was unknown or negative (IHC0/1+ or FISH-) at study entry. **Methods:** Between Jan 2004 and Jul 2005, 580 first-line pts from 24 countries were stratified by metastatic site and randomized 1:1 to 1500 mg lapatinib QD + 175 mg/m² paclitaxel q3w or placebo QD + 175 mg/m² paclitaxel q3w. Primary endpoint was TTP; secondary endpoints were AEs, ORR, PFS, CBR, RFS, and OS. Archived tumor tissue and/or slides obtained from the most recent biopsy were centrally analyzed in blinded fashion for HER2 (IHC and FISH) and ER/PR (IHC). Based on these results, pts were categorized into 3 groups: HER2+, luminal, and basal.

Results and Conclusions: Biomarkers were correlated with clinical efficacy in 579 pts; 542 (93%) pts had tissue available for central analysis. 91 (18%) pts were determined to be HER2+ by FISH or IHC3+. In the HER2+ subset, a statistically significant improvement was observed in lapatinib + paclitaxel vs paclitaxel-treated patients in both median TTP (35.1 v 25.1 wks, HR = 0.57, 95% CI 0.34, 0.93, $p = 0.0107$) and ORR (59.6% v 35.9%, odds ratio = 2.9, 95% CI 1.1, 7.9, $p = 0.027$). Efficacy data in subgroups of patients based on hormone receptor expression levels and breast cancer subtype will be reported. Overall survival data will be available at the time of presentation.

In conclusion, lapatinib in combination with paclitaxel demonstrated statistically significant clinical activity as measured by TTP/PFS and ORR in a targeted population of HER2+ pts with metastatic BC.

2098

ORAL

BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)

T. Pienkowski¹, M. Pegram², J. Forbes³, V. Valero⁴, W. Eiermann⁵, G. Von Minckwitz⁶, M. Martin⁷, J. Crown⁸, on behalf of BCIRG Investigators. ¹Marii Skłodowska Curie, Head of Breast Cancer, Warsaw, Poland; ²UCLA, Jonsson cancer Ctr, Los Angeles, USA; ³University of Newcastle, ANZ BCTG, Newcastle, Australia; ⁴Univ of Texas, MD Anderson Cancer Ctr, Houston, USA; ⁵Frauenklinik vom RK, Munchen, Germany; ⁶Universitätsklinikum, Frankfurt, Germany; ⁷GEICAM, Madrid, Spain; ⁸ICORG, Dublin, Ireland

Background: Based on preclinical synergism between docetaxel (T), carboplatin (C) and trastuzumab (H), BCIRG conducted a phase III trial in HER2-positive MBC to evaluate efficacy and safety of H in combination with T or TC.

Methods: 263 patients (pts) with HER2 FISH+ MBC were randomized to TH (H with T 100 mg/m²) or TCH (H with T 75 mg/m² and C AUC=6). Chemotherapy was given every 3 weeks (q3w) for 8 cycles with weekly H at 2 mg/kg (loading dose of 4 mg/kg) followed by H q3w at 6 mg/kg until progression. Pts were stratified by centre and prior (neo) adjuvant taxane chemotherapy. Primary endpoint was Time To disease Progression (TTP). Secondary endpoints include overall survival, response rate, duration of response (DR), clinical benefit (CB) and safety. In addition, a sub study on Serum HER2 Extra Cellular Domain (ECD) was conducted on the 89% of subjects with levels >15 ng/mL at the time of metastatic disease (86% in TH-treated subjects vs. 92% in TCH-treated subjects).

Results: 131 pts were treated in each arm Pt characteristics were well balanced in both groups. A first efficacy analysis was conducted at 204 events. There was no significant difference between TH and TCH in median TTP (11.1 vs 10.4 mos, $p = 0.57$), ORR (73% in both arms), DR (10.7 vs 9.4 mos) and CB (67% in both arms). At 39 months of median follow-up, median overall survival was 36.40 and 36.57 months in TH and TCH arms respectively. More patients on TCH received the max number of chemotherapy cycles, and numerically fewer patients on TCH discontinued treatment as a result of non hematological toxicity. The most common gr 3/4